Table 1 The EC50 (half effective concentration) of all compounds against NF-κB, TLR4, and IFN-γ signaling pathways and the cytotoxicity (CC50, half cytotoxic concentration) in AD-293 and Hela cells.
From: Attenuation of Innate Immunity by Andrographolide Derivatives Through NF-κB Signaling Pathway
cmpd | EC50 in AD-293 (μM) | EC50 in Hela (μM) | ||||
|---|---|---|---|---|---|---|
NF-κBa | TLR4b | IFN-γc | CC50d | NF-κBa | CC50d | |
Andrographolide (1) | >10 | >10 | >10 | >10 | >10 | >10 |
2a | >10 | 5.76 ± 1.40 | >10 | >10 | >10 | >10 |
2b | >10 | 3.35 ± 0.36 | >10 | >10 | 6.22 ± 0.60 | >10 |
3a | >10 | 5.36 ± 0.58 | >10 | >10 | >10 | >10 |
3b | 8.97 ± 1.03 | 3.49 ± 0.34 | >10 | >10 | 2.00 ± 0.66 | >10 |
4a | 8.85 ± 1.06 | 0.90 ± 0.14 | >10 | >10 | >10 | >10 |
4b | >10 | 3.32 ± 0.72 | >10 | >10 | 5.48 ± 0.39 | >10 |
5a | 10.37 ± 0.71 | 5.79 ± 0.96 | >10 | >10 | 4.89 ± 0.28 | >10 |
5b | 7.54 ± 1.33 | 5.98 ± 0.30 | >10 | >10 | 2.31 ± 0.60 | >10 |
6a | 7.92 ± 0.42 | 3.55 ± 0.07 | >10 | >10 | >10 | >10 |
6b | >10 | 7.67 ± 0.67 | >10 | >10 | >10 | >10 |
7b | >10 | >10 | >10 | >10 | 5.48 ± 0.34 | >10 |
8b | >10 | >10 | >10 | >10 | >10 | >10 |
9b | >10 | >10 | >10 | >10 | >10 | >10 |
10b | >10 | >10 | >10 | >10 | >10 | >10 |
11ba | >10 | >10 | >10 | >10 | >10 | >10 |
11bb | >10 | >10 | >10 | >10 | >10 | >10 |
12ba | >10 | >10 | >10 | >10 | >10 | >10 |
12bb | >10 | >10 | >10 | >10 | >10 | >10 |
